Contraindicated in:
Use Cautiously in:
CNS: headache, anxiety, hallucinations, insomnia, irritability, sleep disturbances.
CV: QT INTERVAL PROLONGATION, tachycardia.
Derm: rash.
GI: abdominal pain, dry mouth, nausea.
Metab: cataplexy, ↓ appetite.
MS: pain.
Resp: upper respiratory tract infection.
Drug-Drug:
Hepatic Impairment
Renal Impairment
Therapeutic Classification: central nervous system stimulants
Pharmacologic Classification: histamine H3 antagonist/agonist
Absorption: 90% absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Protein Binding: 9196%.
Metabolism/Excretion: Primarily metabolized by the liver by the CYP2D6 isoenzyme, and to a lesser extent by the CYP3A4 isoenzyme; the CYP2D6 enzyme system exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly ↑ pitolisant concentrations and an ↑ risk of adverse effects).Primarily excreted in urine (90%; <2% as unchanged drug), with only 2% excreted in feces.
Half-life: 20 hr.
NDC Code*